16 Followers on Owler

AskBio

AskBio is a biotechnology firm that develops and commercializes AAV gene therapies for the treatment of muscular dystrophy and genetic disorders. Read more

Sheila Mikhail's photo - Co-Founder & CEO of AskBio

Co-Founder & CEO

Sheila Mikhail

CEO Approval Rating

89/100

Founded:

2001

Status:

PrivateAcquired by Bayer AG

ASKBIO TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Voyager is seen as one of AskBio's top competitors. Voyager was founded in 2014, and is headquartered in Cambridge, Massachusetts. Like AskBio, Voyager also competes in the Biotechnology industry. Voyager generates $158.1M more revenue vs. AskBio.

AavantiBio is a top competitor of AskBio. AavantiBio was founded in 2017, and its headquarters is in Cambridge, Massachusetts. Like AskBio, AavantiBio also competes in the Biotechnology field. AavantiBio has 295 fewer employees than AskBio.

Reata is AskBio's #3 rival. Reata was founded in Plano, Texas} in 2002. Like AskBio, Reata also works within the Biotechnology industry. Compared to AskBio, Reata generates $4.4M less revenue.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 325 a good estimate for AskBio's Employee count?

AskBio Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Brainvectis SAS

Apr 2020

Source »
undisclosed
BrainVectis is a biotechnology company that develops and commercializes gene therapies for the treatment for neurodegenerative diseases.

-

Technology Assets of Rovermed Biosciences

Sep 2019

Source »
undisclosed
-

These are all the companies that AskBio has acquired. AskBio has acquired 2 companies and its latest acquisition was Brainvectis SAS in Apr 2020. BrainVectis is a biotechnology company that develops and commercializes gene therapies for the treatment for neurodegenerative diseases.

AskBio Funding History

Since AskBio was founded in 2001, it has participated in 3 rounds of funding. In total AskBio has raised $239.3M. AskBio's last funding round was on Sep 2020 for a total of $2.7M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Grant
Sep 2020
$2.7M

Scottish Enterprise

Equity
Apr 2019
$235M
Grant
Jul 2004
$1.6M

Since AskBio was founded in 2001, it has participated in 3 rounds of funding. In total AskBio has raised $239.3M. AskBio's last funding round was on Sep 2020 for a total of $2.7M

AskBio Investments

No recent investments found related to AskBio

These are all the companies that AskBio has invested in. AskBio has invested 2 companies and its latest investment was Brainvectis SAS in Apr 2020. BrainVectis is a biotechnology company that develops and commercializes gene therapies for the treatment for neurodegenerative diseases.

AskBio News

January 28, 2021BioSpace

AskBio Adds CNS Gene Therapy Programs in Parkinson's Disease and Multiple System AtrophyClinical team led by neurological gene therapy expert, Dr. Krystof Bankiewicz, joins AskBio

Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therap... See more »
January 12, 2021The Business Journals: Raleigh/Durham

AskBio taps industry vet, UNC grad for new C-suite role in wake of Bayer deal

In the wake of its potential $4 billion deal with Bayer, AskBio is expanding its leadership team.... See more »
November 19, 2020BioSpace

AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaGene therapy MMA-101

Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announc... See more »
October 29, 2020Zacks

ETFs in Focus on Bayer's Bet on Gene Therapy

Bayer has made a big bet on gene therapy by announcing the acquisition of U.S. biotech firm Asklepios... See more »
October 28, 2020WRAL TechWire

AskBio to be hiring 'across the board,' CEO says after $4B deal with Bayer

After sale to Bayer, gene therapy firm AskBio plans expansion and hiring, says its CEO in an exclusiv... See more »
October 27, 2020Pharmabiz

Bayer buys USbased biopharma company, Asklepios BioPharma for US$ 4 billion

Bayer AG announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US─headquartered ... See more »
October 27, 2020PE Hub Network

TPG's AskBio stake more than doubles amid sale to Bayer

Bayer agreed to pay $2bn upfront for the TPG-backed gene therapy company, plus a potential for anothe... See more »

AskBio Press Releases

December 11, 2020GlobeNewswire

AskBio CSO Jude Samulski Named 2020 Business Person of the Year by Triangle Business Journal

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (As... See more »
October 20, 2020GlobeNewswire

Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia

WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Selecta Bioscien... See more »
September 2, 2020Sciad Newswire

AskBio Awarded 2m Scottish Enterprise R&D Grant to Help Reduce Barriers to Mainstream Gene Therapy

Edinburgh, UK, 2nd September 2020 / Sciad Newswire / Asklepios BioPharmaceutical, Inc. (AskBio), a le... See more »
April 7, 2020centralcharts

Don Haut, PhD, Joins AskBio as Chief Business Officer

RESEARCH TRIANGLE PARK, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical , Inc. (... See more »
October 24, 2019PR Newswire

Sheila Mikhail, AskBio CEO and Cofounder, Named Springboard Enterprises' 2019 Northstar Honoree

RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2019 /PRNewswire/ -- Springboard Enterprises has named Sheila ... See more »
January 29, 2019PRWeb

AskBio Announces First Patient Dosed with Gene Therapy in Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease

Initial clinical study to evaluate ACTUS-101 over 52 weeks that could improve quality of life for tho... See more »

AskBio Videos

Social Media

AskBio Headquarters

20 T.W. Alexander Drive Suite 110

Durham, North Carolina27709

1-919-561-6210

Driving Directions »

Trending Companies

AskBio Summary

ABOUT

Overview

AskBio is a biotechnology firm that develops and commercializes AAV gene therapies for the treatment of muscular dystrophy and genetic disorders. AskBio was founded in 2001. AskBio's headquarters is located in Durham, North Carolina, USA 27709. It has...

CEO

AskBio's Co-Founder & CEO, Sheila Mikhail, currently has an approval rating of 89%. AskBio's primary competitors are Voyager, AavantiBio & Reata.

Website

askbio.com

Frequently Asked Questions about AskBio

  1. When was AskBio founded?

    AskBio was founded in 2001
  2. Who is AskBio's CEO?

    AskBio's CEO is Sheila Mikhail
  3. How much revenue does AskBio generate?

    AskBio generates $13M in revenue
  4. How much funding does AskBio have?

    AskBio has historically raised $239.3M in funding
  1. Where is AskBio's headquarters?

    AskBio's headquarters is in Durham North Carolina, USA
  2. How many employees does AskBio have?

    AskBio has 325 employees
  3. What sector does AskBio operate in?

    AskBio is in Biotechnology
  4. Who are AskBio's competitors?

    AskBio's top competitors are Voyager, AavantiBio, Reata